Rank #1760XFOR

X4 Pharmaceuticals, Inc.

$3.10

3.68% (Daily)

Market Cap

$271.05M

Revenue

$33.98M

Rank by MCap

#1760

Sector

Healthcare

Industry

Biotechnology

CEO

Dr. Adam R. Craig M.B.A., M.D., Ph.D.

Headquarters

Boston, MA

Employees

143

About X4 Pharmaceuticals, Inc.

X4 Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases of the immune system. It offers XOLREMDI, an orally bioavailable selective antagonist of chemokine receptor C-X-C chemokine receptor type 4 (CXCR4) for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome. The company also develops mavorixafor that is in Phase 3 4WARD clinical ...